Breaking News: Innovent Presents Exciting Phase 1 Clinical Data for IBI363, a Revolutionary PD-1/IL-2 Bispecific Antibody Fusion Protein, in Advanced Non-Small Cell Lung Cancer at 2024 WCLC!
Welcome to the World of Biopharmaceuticals! An Exciting Announcement from Innovent Biologics SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) has recently made waves in the biopharmaceutical world with the presentation of Phase 1 clinical data for their groundbreaking IBI363 drug. IBI363 is a first-in-class PD-1/IL-2α-bias bispecific…